Company Creation

Create. Grow. Lead.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. Spun out of CPDC in 2016, Fusion grew from the innovative R&D being performed at CPDC on Targeted Alpha Therapies (TATs). Fusion Pharmaceuticals was acquired by AstraZeneca, a global, science-led, patient-focused biopharmaceutical company, that develops innovative medicines for millions of patients worldwide in 2024 for up to $2.4B USD. To learn more about Fusion, please visit fusionpharma.com

AtomVie Global Radiopharma Inc. (AtomVie) is a global leading Contract Development and Manufacturing Organization (CDMO) for radiotherapeutics. Spun out of CPDC in 2022, AtomVie has leveraged 10 years of expertise in GMP manufacturing and global distribution of radiopharmaceuticals by CPDC. AtomVie offers a full range of scientific, regulatory, quality, logistics, and business expertise combined with specialized infrastructure for the development of radiotherapeutics from Phase 1 to the commercial marketplace. To learn more about AtomVie, please visit atomvie.com

Alternative Radioisotope Technologies for Medical Science (ARTMS) is a commercial-stage company which specialises in the physics, chemistry and materials science of cyclotron-produced radionuclides. Its core technology platform, the QUANTM Irradiation System™ (QIS™), is a complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of commercially important medical isotopes. ARTMS was founded in 2013 by the CPDC, TRIUMF, Lawson Health Research Institute, and BC Cancer. ARTMS was acquired by Telix Pharmaceuticals in 2024 for up to $82M USD. To learn more about ARTMS, please visit artms.ca